Home Lymphoma Myc expression may predict remission response in diffuse large B-cell lymphoma

Myc expression may predict remission response in diffuse large B-cell lymphoma

65
0

December 09, 2020

1 min watch


Source/Disclosures


Source:

Jaeger, U et al. Abstract 1194. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.


Disclosures:
Locke reports holding a scientific advisory role for Allogene, Celgene, GammaDelta Therapeutics, Kite, Novartis and Wugen; and acting as consultant with grant options for Cellular Biomedicine Group Inc.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, discussed follow-up data from the JULIET trial presented at the ASH Annual Meeting and Exposition.

He talked about gauging therapy response with Myc expression

“Patients who had a high Myc expression by immunohistochemistry had worse outcomes. This is interesting because in the pivotal CAR T-cell therapy trials for diffuse large B-cell lymphoma, we haven’t seen that double hit lymphoma or double expressor lymphoma has really been a predictor for worse outcomes. Here, they quite simply looked by immunohistochemistry for Myc expression,” Locke told Healio in a video interview.

https://www.healio.com/news/hematology-oncology/20201209/video-myc-expression-may-predict-remission-response-in-diffuse-large-bcell-lymphoma

This site uses Akismet to reduce spam. Learn how your comment data is processed.